BACKGROUND: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder most often caused by mutation in the endoglin or ALK1 genes. A distinct syndrome combines the clinical features of HHT and juvenile polyposis (JP) and has been associated with SMAD4 mutation. The aim of this study was to describe the phenotype of patients with JP-HHT and SMAD4 mutations and to compare this phenotype with HHT or JP patients with mutations other than SMAD4. METHODS: Patients prospectively enrolled in the Toronto HHT and JP databases who underwent genotyping were included. The phenotypic characteristics of JP-HHT patients with SMAD4 mutations and patients with mutations other than SMAD4 were analyzed and compared. RESULTS: Three hundred and fifty-eight patients underwent genetic testing (HHT, n = 332; JP, n = 26). Among fourteen patients identified with SMAD4 mutations, ten met the clinical diagnostic criteria for both JP and HHT (71%). Patients with SMAD4 mutations had 100% penetrance of the polyposis phenotype. All patients with JP and SMAD4 mutation had features of HHT. Three JP-HHT patients developed early onset colorectal cancer (CRC) (mean age 28 years). JP-HHT patients with SMAD4 mutation had a significantly higher rate of anemia than HHT patients with mutations other than SMAD4. CONCLUSIONS: Patients with HHT and SMAD4 mutations are at significant risk of JP and CRC. The gastrointestinal phenotype is similar to JP patients without SMAD4 mutation. It is essential for HHT patients to undergo genetic testing to determine if they have SMAD4 mutations so that appropriate gastrointestinal screening and surveillance for JP and CRC can be completed.
BACKGROUND:Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder most often caused by mutation in the endoglin or ALK1 genes. A distinct syndrome combines the clinical features of HHT and juvenile polyposis (JP) and has been associated with SMAD4 mutation. The aim of this study was to describe the phenotype of patients with JP-HHT and SMAD4 mutations and to compare this phenotype with HHT or JP patients with mutations other than SMAD4. METHODS:Patients prospectively enrolled in the Toronto HHT and JP databases who underwent genotyping were included. The phenotypic characteristics of JP-HHTpatients with SMAD4 mutations and patients with mutations other than SMAD4 were analyzed and compared. RESULTS: Three hundred and fifty-eight patients underwent genetic testing (HHT, n = 332; JP, n = 26). Among fourteen patients identified with SMAD4 mutations, ten met the clinical diagnostic criteria for both JP and HHT (71%). Patients with SMAD4 mutations had 100% penetrance of the polyposis phenotype. All patients with JP and SMAD4 mutation had features of HHT. Three JP-HHTpatients developed early onset colorectal cancer (CRC) (mean age 28 years). JP-HHTpatients with SMAD4 mutation had a significantly higher rate of anemia than HHTpatients with mutations other than SMAD4. CONCLUSIONS:Patients with HHT and SMAD4 mutations are at significant risk of JP and CRC. The gastrointestinal phenotype is similar to JP patients without SMAD4 mutation. It is essential for HHTpatients to undergo genetic testing to determine if they have SMAD4 mutations so that appropriate gastrointestinal screening and surveillance for JP and CRC can be completed.
Authors: Pinar Bayrak-Toydemir; Jamie McDonald; Nurten Akarsu; Reha M Toydemir; Fernanda Calderon; Timur Tuncali; Wei Tang; Franklin Miller; Rong Mao Journal: Am J Med Genet A Date: 2006-10-15 Impact factor: 2.802
Authors: N L Prigoda; S Savas; S A Abdalla; B Piovesan; D Rushlow; K Vandezande; E Zhang; H Ozcelik; B L Gallie; M Letarte Journal: J Med Genet Date: 2006-05-11 Impact factor: 6.318
Authors: J R Howe; J L Bair; M G Sayed; M E Anderson; F A Mitros; G M Petersen; V E Velculescu; G Traverso; B Vogelstein Journal: Nat Genet Date: 2001-06 Impact factor: 38.330
Authors: C J Gallione; J A Richards; T G W Letteboer; D Rushlow; N L Prigoda; T P Leedom; A Ganguly; A Castells; J K Ploos van Amstel; C J J Westermann; R E Pyeritz; D A Marchuk Journal: J Med Genet Date: 2006-04-13 Impact factor: 6.318
Authors: Eline Soer; Wouter H de Vos Tot Nederveen Cappel; Marjolijn J L Ligtenberg; Freek Moll; Robert G Pierik; Juda Vecht; Hans F A Vasen; Antoine Flierman Journal: Fam Cancer Date: 2015-12 Impact factor: 2.375
Authors: Jane-Claire B Williams; J Kent Hamilton; Michelle Shiller; Laurice Fischer; Gregory Deprisco; C Richard Boland Journal: Proc (Bayl Univ Med Cent) Date: 2012-10
Authors: Samuel B Jackson; Nicholas P Villano; Jihane N Benhammou; Michael Lewis; Joseph R Pisegna; David Padua Journal: Dig Dis Sci Date: 2017-08-23 Impact factor: 3.199
Authors: Reka Szigeti; Stephanie A Pangas; Dorottya Nagy-Szakal; Scot E Dowd; Robert J Shulman; Anthony P Olive; Edwina J Popek; Milton J Finegold; Richard Kellermayer Journal: Ann Clin Lab Sci Date: 2012 Impact factor: 1.256
Authors: Karen E Wain; Marissa S Ellingson; Jamie McDonald; Amanda Gammon; Maegan Roberts; Pavel Pichurin; Ingrid Winship; Douglas L Riegert-Johnson; Jeffrey N Weitzel; Noralane M Lindor Journal: Genet Med Date: 2014-02-13 Impact factor: 8.822